+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lysosomal Disease Treatment Market By Disease Type, By Type of Therapy, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 319 Pages
  • July 2022
  • Region: Global
  • Allied Market Research
  • ID: 5671178
Description Jump to:
The global lysosomal disease treatment market was valued at $7,572.97 million in 2021, and is projected to reach $14,090.39 million by 2031, registering a CAGR of 6.4% from 2022 to 2031.

Lysosomal disease is caused due to deficiency or absence of lysosomal acid lipase enzyme. The deficiency causes structural abnormalities of lysosome, result in storage of several toxic substances in the body cells. There are about 50 different types of these illnesses, which can harm heart, brain, skin, skeleton, and central nervous system among other physical organs. More lysosomal diseases are continuously being identified. Many lysosomal diseases currently lack an approved drug, despite the fact that clinical trials for prospective therapies for some of these disorders are now in progress.

A set of inherited metabolic diseases known as lysosomal storage disorders are brought on by enzyme deficits in different body cells. Key driver for growth of the global lysosomal disease treatment market includes increasing diagnosis rate, owing to increase in awareness and financial incentives for orphan drug development, which treats lysosomal diseases. In addition, rise in prevalence of lysosomal diseases, affordable product cost, increase in pharmaceutical companies for development of novel medications to treat lysosomal diseases are also responsible for growth of the market. Lack of treatment for lysosomal diseases and high cost of treatments are the factors that restrain growth of the market.

The lysosomal disease treatment market is segmented on the basis of disease type, type of therapy, end user, and region. By disease type, the market is divided into Gaucher’s diseases, Fabry diseases, Pompe’s syndrome, Mucopolysaccharidosis, and others. The others segment is further classified into aspartylglucosaminuria, batten disease, cystinosis, and glycogen storage disease II. By type of therapy, the market is fragmented into Enzyme replacement therapy, Stem cell therapy, Substrate reduction therapy, and others. By end user, it is segmented into Hospitals, Clinics, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global lysosomal disease treatment market include Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioMari, Chiese Farmaceutici SpA, Eli Lilly Company, Horizon Therapeutics Plc, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Leadient Biosciences, Inc Novartis AG, Orphazyme A/S, Pfizer Inc, Recordati SpA, Sanofi (Genzyme Corporation), Sigilon Therapeutics, Inc, and Takeda Pharmaceutical Company Limited (Shire Plc) Valerion Therapeutics, Llc, and Viatris Inc (Mylan NV).

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lysosomal disease treatment market analysis from 2021 to 2031 to identify the prevailing lysosomal disease treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the lysosomal disease treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global lysosomal disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Gaucher's Diseases
  • Fabry Diseases
  • Pompe’s Syndrome
  • Mucopolysaccharidosis
  • Others

By Type of Therapy

  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • Substrate Reduction Therapy
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Amicus Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc
  • BioMarin
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Sigilon Therapeutics, Inc

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Gaucher's Diseases
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Fabry Diseases
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Pompe’s Syndrome
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Mucopolysaccharidosis
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Enzyme Replacement Therapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Stem Cell Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Substrate Reduction Therapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Clinics
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Type of Therapy
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Type of Therapy
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Type of Therapy
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Type of Therapy
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Type of Therapy
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Type of Therapy
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Type of Therapy
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Type of Therapy
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Type of Therapy
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Type of Therapy
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Type of Therapy
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Type of Therapy
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Type of Therapy
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Type of Therapy
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Type of Therapy
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Type of Therapy
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Type of Therapy
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Type of Therapy
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Type of Therapy
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Type of Therapy
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Type of Therapy
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Type of Therapy
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Type of Therapy
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Amicus Therapeutics, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Alexion Pharmaceuticals, Inc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 BioMarin
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Johnson & Johnson
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novartis AG
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Pfizer Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Sanofi
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Takeda Pharmaceutical Company Limited
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Eli Lilly and Company
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sigilon Therapeutics, Inc
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
List of Tables
Table 1. Global Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 2. Lysosomal Disease Treatment Market Size, for Gaucher's Diseases, by Region, 2021-2031 ($Million)
Table 3. Lysosomal Disease Treatment Market for Gaucher's Diseases by Country, 2021-2031 ($Million)
Table 4. Lysosomal Disease Treatment Market Size, for Fabry Diseases, by Region, 2021-2031 ($Million)
Table 5. Lysosomal Disease Treatment Market for Fabry Diseases by Country, 2021-2031 ($Million)
Table 6. Lysosomal Disease Treatment Market Size, for Pompe's Syndrome, by Region, 2021-2031 ($Million)
Table 7. Lysosomal Disease Treatment Market for Pompe's Syndrome by Country, 2021-2031 ($Million)
Table 8. Lysosomal Disease Treatment Market Size, for Mucopolysaccharidosis, by Region, 2021-2031 ($Million)
Table 9. Lysosomal Disease Treatment Market for Mucopolysaccharidosis by Country, 2021-2031 ($Million)
Table 10. Lysosomal Disease Treatment Market Size, for Others, by Region, 2021-2031 ($Million)
Table 11. Lysosomal Disease Treatment Market for Others by Country, 2021-2031 ($Million)
Table 12. Global Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 13. Lysosomal Disease Treatment Market Size, for Enzyme Replacement Therapy, by Region, 2021-2031 ($Million)
Table 14. Lysosomal Disease Treatment Market for Enzyme Replacement Therapy by Country, 2021-2031 ($Million)
Table 15. Lysosomal Disease Treatment Market Size, for Stem Cell Therapy, by Region, 2021-2031 ($Million)
Table 16. Lysosomal Disease Treatment Market for Stem Cell Therapy by Country, 2021-2031 ($Million)
Table 17. Lysosomal Disease Treatment Market Size, for Substrate Reduction Therapy, by Region, 2021-2031 ($Million)
Table 18. Lysosomal Disease Treatment Market for Substrate Reduction Therapy by Country, 2021-2031 ($Million)
Table 19. Lysosomal Disease Treatment Market Size, for Others, by Region, 2021-2031 ($Million)
Table 20. Lysosomal Disease Treatment Market for Others by Country, 2021-2031 ($Million)
Table 21. Global Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 22. Lysosomal Disease Treatment Market Size, for Hospitals, by Region, 2021-2031 ($Million)
Table 23. Lysosomal Disease Treatment Market for Hospitals by Country, 2021-2031 ($Million)
Table 24. Lysosomal Disease Treatment Market Size, for Clinics, by Region, 2021-2031 ($Million)
Table 25. Lysosomal Disease Treatment Market for Clinics by Country, 2021-2031 ($Million)
Table 26. Lysosomal Disease Treatment Market Size, for Others, by Region, 2021-2031 ($Million)
Table 27. Lysosomal Disease Treatment Market for Others by Country, 2021-2031 ($Million)
Table 28. Lysosomal Disease Treatment Market, by Region, 2021-2031 ($Million)
Table 29. North America Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 30. North America Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 31. North America Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 32. North America Lysosomal Disease Treatment Market, by Country, 2021-2031 ($Million)
Table 33. U.S. Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 34. U.S. Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 35. U.S. Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 36. Canada Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 37. Canada Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 38. Canada Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 39. Mexico Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 40. Mexico Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 41. Mexico Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 42. Europe Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 43. Europe Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 44. Europe Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 45. Europe Lysosomal Disease Treatment Market, by Country, 2021-2031 ($Million)
Table 46. Germany Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 47. Germany Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 48. Germany Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 49. France Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 50. France Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 51. France Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 52. U.K. Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 53. U.K. Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 54. U.K. Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 55. Italy Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 56. Italy Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 57. Italy Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 58. Spain Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 59. Spain Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 60. Spain Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 61. Rest of Europe Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 62. Rest of Europe Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 63. Rest of Europe Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 64. Asia-Pacific Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 65. Asia-Pacific Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 66. Asia-Pacific Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 67. Asia-Pacific Lysosomal Disease Treatment Market, by Country, 2021-2031 ($Million)
Table 68. Japan Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 69. Japan Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 70. Japan Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 71. China Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 72. China Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 73. China Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 74. Australia Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 75. Australia Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 76. Australia Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 77. India Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 78. India Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 79. India Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 80. South Korea Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 81. South Korea Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 82. South Korea Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 83. Rest of Asia-Pacific Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 84. Rest of Asia-Pacific Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 85. Rest of Asia-Pacific Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 86. LAMEA Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 87. LAMEA Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 88. LAMEA Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 89. LAMEA Lysosomal Disease Treatment Market, by Country, 2021-2031 ($Million)
Table 90. Brazil Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 91. Brazil Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 92. Brazil Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 93. Saudi Arabia Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 94. Saudi Arabia Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 95. Saudi Arabia Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 96. South Africa Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 97. South Africa Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 98. South Africa Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 99. Rest of LAMEA Lysosomal Disease Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 100. Rest of LAMEA Lysosomal Disease Treatment Market, by Type of Therapy, 2021-2031 ($Million)
Table 101. Rest of LAMEA Lysosomal Disease Treatment Market, by End-user, 2021-2031 ($Million)
Table 102. Amicus Therapeutics, Inc.: Company Snapshot
Table 103. Amicus Therapeutics, Inc.: Operating Segments
Table 104. Amicus Therapeutics, Inc.: Product Portfolio
Table 105. Amicus Therapeutics, Inc.: Net Sales
Table 106. Amicus Therapeutics, Inc.: Key Stratergies
Table 107. Alexion Pharmaceuticals, Inc: Company Snapshot
Table 108. Alexion Pharmaceuticals, Inc: Operating Segments
Table 109. Alexion Pharmaceuticals, Inc: Product Portfolio
Table 110. Alexion Pharmaceuticals, Inc: Net Sales
Table 111. Alexion Pharmaceuticals, Inc: Key Stratergies
Table 112. Biomarin: Company Snapshot
Table 113. Biomarin: Operating Segments
Table 114. Biomarin: Product Portfolio
Table 115. Biomarin: Net Sales
Table 116. Biomarin: Key Stratergies
Table 117. Johnson & Johnson: Company Snapshot
Table 118. Johnson & Johnson: Operating Segments
Table 119. Johnson & Johnson: Product Portfolio
Table 120. Johnson & Johnson: Net Sales
Table 121. Johnson & Johnson: Key Stratergies
Table 122. Novartis Ag: Company Snapshot
Table 123. Novartis Ag: Operating Segments
Table 124. Novartis Ag: Product Portfolio
Table 125. Novartis Ag: Net Sales
Table 126. Novartis Ag: Key Stratergies
Table 127. Pfizer Inc.: Company Snapshot
Table 128. Pfizer Inc.: Operating Segments
Table 129. Pfizer Inc.: Product Portfolio
Table 130. Pfizer Inc.: Net Sales
Table 131. Pfizer Inc.: Key Stratergies
Table 132. Sanofi: Company Snapshot
Table 133. Sanofi: Operating Segments
Table 134. Sanofi: Product Portfolio
Table 135. Sanofi: Net Sales
Table 136. Sanofi: Key Stratergies
Table 137. Takeda Pharmaceutical Company Limited: Company Snapshot
Table 138. Takeda Pharmaceutical Company Limited: Operating Segments
Table 139. Takeda Pharmaceutical Company Limited: Product Portfolio
Table 140. Takeda Pharmaceutical Company Limited: Net Sales
Table 141. Takeda Pharmaceutical Company Limited: Key Stratergies
Table 142. Eli Lilly and Company: Company Snapshot
Table 143. Eli Lilly and Company: Operating Segments
Table 144. Eli Lilly and Company: Product Portfolio
Table 145. Eli Lilly and Company: Net Sales
Table 146. Eli Lilly and Company: Key Stratergies
Table 147. Sigilon Therapeutics, Inc: Company Snapshot
Table 148. Sigilon Therapeutics, Inc: Operating Segments
Table 149. Sigilon Therapeutics, Inc: Product Portfolio
Table 150. Sigilon Therapeutics, Inc: Net Sales
Table 151. Sigilon Therapeutics, Inc: Key Stratergies
List of Figures
Figure 1. Lysosomal Disease Treatment Market Segmentation
Figure 2. Lysosomal Disease Treatment Market,2021-2031
Figure 3. Lysosomal Disease Treatment Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Lysosomal Disease Treatment Market:Drivers, Restraints and Opportunities
Figure 12. Lysosomal Disease Treatment Market,By Disease Type,2021(%)
Figure 13. Comparative Share Analysis of Gaucher's Diseases Lysosomal Disease Treatment Market,2021-2031(%)
Figure 14. Comparative Share Analysis of Fabry Diseases Lysosomal Disease Treatment Market,2021-2031(%)
Figure 15. Comparative Share Analysis of Pompe's Syndrome Lysosomal Disease Treatment Market,2021-2031(%)
Figure 16. Comparative Share Analysis of Mucopolysaccharidosis Lysosomal Disease Treatment Market,2021-2031(%)
Figure 17. Comparative Share Analysis of Others Lysosomal Disease Treatment Market,2021-2031(%)
Figure 18. Lysosomal Disease Treatment Market,By Type of Therapy,2021(%)
Figure 19. Comparative Share Analysis of Enzyme Replacement Therapy Lysosomal Disease Treatment Market,2021-2031(%)
Figure 20. Comparative Share Analysis of Stem Cell Therapy Lysosomal Disease Treatment Market,2021-2031(%)
Figure 21. Comparative Share Analysis of Substrate Reduction Therapy Lysosomal Disease Treatment Market,2021-2031(%)
Figure 22. Comparative Share Analysis of Others Lysosomal Disease Treatment Market,2021-2031(%)
Figure 23. Lysosomal Disease Treatment Market,By End-user,2021(%)
Figure 24. Comparative Share Analysis of Hospitals Lysosomal Disease Treatment Market,2021-2031(%)
Figure 25. Comparative Share Analysis of Clinics Lysosomal Disease Treatment Market,2021-2031(%)
Figure 26. Comparative Share Analysis of Others Lysosomal Disease Treatment Market,2021-2031(%)
Figure 27. Lysosomal Disease Treatment Market by Region,2021
Figure 28. U.S. Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 29. Canada Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 30. Mexico Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 31. Germany Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 32. France Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 33. U.K. Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 34. Italy Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 35. Spain Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 36. Rest of Europe Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 37. Japan Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 38. China Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 39. Australia Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 40. India Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 41. South Korea Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 42. Rest of Asia-Pacific Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 43. Brazil Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 44. Saudi Arabia Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 45. South Africa Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 46. Rest of LAMEA Lysosomal Disease Treatment Market,2021-2031($Million)
Figure 47. Top Winning Strategies, by Year
Figure 48. Top Winning Strategies, by Development
Figure 49. Top Winning Strategies, by Company
Figure 50. Product Mapping of Top 10 Players
Figure 51. Competitive Dashboard
Figure 52. Competitive Heatmap of Top 10 Key Players
Figure 53. Amicus Therapeutics, Inc..: Net Sales ,($Million)
Figure 54. Alexion Pharmaceuticals, Inc.: Net Sales ,($Million)
Figure 55. Biomarin.: Net Sales ,($Million)
Figure 56. Johnson & Johnson.: Net Sales ,($Million)
Figure 57. Novartis AG.: Net Sales ,($Million)
Figure 58. Pfizer Inc..: Net Sales ,($Million)
Figure 59. Sanofi.: Net Sales ,($Million)
Figure 60. Takeda Pharmaceutical Company Limited.: Net Sales ,($Million)
Figure 61. Eli Lilly and Company.: Net Sales ,($Million)
Figure 62. Sigilon Therapeutics, Inc.: Net Sales ,($Million)

Executive Summary

According to the report, titled, “Lysosomal Disease Treatment Market," the lysosomal disease treatment market was valued at $7.6 billion in 2021, and is estimated to reach $14.1 billion by 2031, growing at a CAGR of 6.4% from 2022 to 2031.

Lysosomal disease (LD) is a hereditary metabolic disorder brought on by inadequate lysosomal enzyme synthesis. Human body contains over 50 different forms of lysosomal storage disorders. In addition, there are few choices for treating the illness. The lysosomal disease treatment market share is expected to expand as more research and development (R&D) activities are conducted in an effort to create an effective treatment. Expanding government programs and investments for development of innovative medications is expected to boost the market growth during the forecast period. Moreover, rise in prevalence of lysosomal disease treatment is expected to boost the lysosomal disease treatment market growth. Introduction of orphan medicines is also anticipated to fuel the market expansion.

Growth in awareness regarding preventative measures for lysosomal diseases and lysosomal disease treatment market trends are anticipated to propel the growth of lysosomal disease treatment market size. The lysosomal disease treatment market is also expected to grow, owing to expansion of pharmaceutical and healthcare industries. However, lack of effective treatments and their high-cost are the factors restrain the market growth. The demand for lysosomal disease treatment significantly decreased after the COVID-19 pandemic. The focus of medical professionals, governments, and general public has moved to containing spread of the virus as a result of quick expansion of the virus. It consequently decreased the need for lysosomal disease treatment. People also stopped going to clinics and hospitals unless they had an emergency. As a result, the COVID-19 pandemic caused severe disruptions in the market for treating lysosomal diseases. Lysosomal disease is group of inherent diseases affects the normal body fuctions of brain, skeletal and central nervous system. During the covid-19 period the need for lysosomal disease treatment decreased significantly. However, the diagnostic methods used for the lysosomal diseases are enzyme assay activity, optical fluorometry, mutation scanning, mass spectroscopy and DNA sequencing. In various hospitals screening of newborn for various test including lysosomal disease test is mandatory. According to the U.S. National Library of Medicine 1 in 40,000 to 60,000 males have Fabry's disease. Pompe’s syndrome is affecting about 1 in 40,000 people in the U.S. according to the National Organization for Rare Disorders. Moreover, Pompe’ syndrome affects about 1 in 40,000 people in the U.S., according to the National Organization for Rare Disorders
Coronavirus Severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. The virus was initially referred to as “novel coronavirus 2019” (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020, and by September 1, 2020, over 28.1 million people have been infected globally with over 909,000 deaths. COVID-19 symptoms include fever, cough, and shortness of breath.

Nearly all industries have been impacted by the COVID-19. As coronavirus crises sweep the globe and force healthcare organizations to devote majority of their funds to fighting COVID-19, the outbreak of COVID-19 has resulted in a significant decline in demand for the lysosomal disease treatment across several sectors, particularly the health and pharmaceutical sector. The main cause of the interruptions experienced by patients getting treatment for lysosomal storage disorder in hospitals was the risk of infection. As a result, the COVID-19 outbreak is expected to slow the global market growth for treatments for lysosomal diseases, which will have a negative effect on the market's value in 2022 and beyond
By disease type, the Gaucher's disease segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to increase in incidences of lysosomal diseases and rise in awareness related to early diagnosis of lysosomal diseases.

Depending on type of therapy, the enzyme replacement therapy segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to increasing research and development (R&D) activities to develop an efficient treatment.

On the basis of end user, the hospitals segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in rare diseases and increase in success rate of treatment of lysosomal diseases.

Region wise, North America has the highest lysosomal disease treatment industry share in 2021. Furthermore, availability of products for treatment of lysosomal diseases and high disease prevalence are the major factors responsible for the market growth of this region.

Key Findings of the Study

  • By disease type, the Gaucher's diseases segment dominated the market in 2021, and it is expected to remain dominant throughout the forecast period.
  • On the basis of type of therapy, the enzyme replacement therapy segment dominated the market in 2021.
  • By end user, the hospitals segment dominated the market in 2021.
  • Region wise, North America dominated the market in 2021.

Companies Mentioned

  • Amicus Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc
  • Biomarin
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Sigilon Therapeutics, Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages319
PublishedJuly 2022
Forecast Period2021 - 2031
Estimated Market Value ( USD ) in 2021 $ 7572.97 million
Forecasted Market Value ( USD ) by 2031 $ 14090.39 million
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Lysosomal Storage Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Lysosomal Storage Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 167 Pages
  • Global
Lysosomal Disease Treatment Global Market Report 2024 - Product Image

Lysosomal Disease Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Lysosomal Storage Diseases Market by Disease Type, Type of Therapy, End User - Global Forecast 2025-2030 - Product Image

Lysosomal Storage Diseases Market by Disease Type, Type of Therapy, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Lysosomal Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Lysosomal Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Lysosomal Storage Diseases - Global Strategic Business Report - Product Image

Lysosomal Storage Diseases - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.